Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice

Lars Tönges*, Carsten Buhmann, Stephan Klebe, Jochen Klucken, Eun Hae Kwon, Thomas Müller, David J. Pedrosa, Nils Schröter, Peter Riederer, Paul Lingor

*Corresponding author for this work

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

The clinical presentation of Parkinson’s disease (PD) is both complex and heterogeneous, and its precise classification often requires an intensive work-up. The differential diagnosis, assessment of disease progression, evaluation of therapeutic responses, or identification of PD subtypes frequently remains uncertain from a clinical point of view. Various tissue- and fluid-based biomarkers are currently being investigated to improve the description of PD. From a clinician's perspective, signatures from blood that are relatively easy to obtain would have great potential for use in clinical practice if they fulfill the necessary requirements as PD biomarker. In this review article, we summarize the knowledge on blood-based PD biomarkers and present both a researcher’s and a clinician’s perspective on recent developments and potential future applications.

Original languageEnglish
JournalJournal of Neural Transmission
Early online date15 Apr 2022
DOIs
Publication statusE-pub ahead of print - 15 Apr 2022

Keywords

  • Alpha-synuclein
  • Biomarker
  • Parkinsonian syndromes
  • Parkinson’s disease

Fingerprint

Dive into the research topics of 'Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice'. Together they form a unique fingerprint.

Cite this